Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | MTTP | P55157 | 11/20 | 0.50 |
| ▸ | APOB | P04114 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886439 | 1.00 | PTGS1 (0.53) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL3892763 | 0.85 | GAA (0.47) | PTGS1MTTPAPOBSMN1; SMN2GAA | |
| SCHEMBL3892759 | 0.85 | GAA (0.47) | PTGS1MTTPAPOBSMN1; SMN2GAA | |
| SCHEMBL6788183 | 0.84 | MEN1 (0.54) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6788179 | 0.84 | MEN1 (0.54) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6791269 | 0.83 | PTGS1 (0.59) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6791178 | 0.81 | PTGS1 (0.67) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6793291 | 0.81 | PTGS1 (0.56) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL31393757 | 0.81 | CHRNB2 (0.71) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 | |
| SCHEMBL6789828 | 0.80 | PTGS1 (0.58) | PTGS1MTTPAPOBSMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538124-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-26 | — | — | US | disclosed |
| US-20080275087-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-11-06 | — | — | US | disclosed |
| US-7405307-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-29 | — | — | US | disclosed |
| US-20080009522-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-01-10 | — | — | US | disclosed |
| US-7304167-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7244848-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7135586-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA, NV (BE) | 2006-11-14 | — | — | US | disclosed |
| EP-1339685-B1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128972-A1 | Biphenylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN | 2006-06-15 | — | — | US | disclosed |
| US-20060128973-A1 | Biphenylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN | 2006-06-15 | — | — | US | disclosed |
| US-20040102490-A1 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009522-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, FABP4 | PTGS1 1053/4885MTTP 22/4885APOB 13/4885 |
| US-20080275087-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, FABP4 | PTGS1 1053/4885MTTP 22/4885APOB 13/4885 |
| US-20060128972-A1 | Biphenylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, FABP4 | PTGS1 1053/4885MTTP 22/4885APOB 13/4885 |
| US-20060128973-A1 | Biphenylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, FABP4 | PTGS1 1053/4885MTTP 22/4885APOB 13/4885 |
| US-20040102490-A1 | Biphenylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, FABP4 | PTGS1 424/4885MTTP 37/4885APOB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.